Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Vertex Pharmaceuticals Incorporated (VRTX - Snapshot Report) recently received regulatory approval in Australia for its cystic fibrosis (CF) drug, Kalydeco (ivacaftor). The Therapeutic Goods Administration (TGA) of Australia approved the drug for CF patients (≥ 6 years of age) who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

We note that Kalydeco is already approved in the US, EU and Canada. Kalydeco, which delivered revenues of $171.6 million in 2012, is off to a strong start and should continue performing well in 2013.

Vertex Pharma reported rapid uptake in a major part of eligible patients in the US in the first quarter of 2013. While US sales were $50 million, ex-US sales were about $12 million in the first quarter of 2013. Sales should benefit from reimbursement in additional European countries and launch in new markets.

We note that Vertex Pharma is also working on expanding Kalydeco’s label. Kalydeco is currently in three phase III studies in which it is being evaluated as a monotherapy in CF patients (≥ 6 years of age) who have at least one copy of the R117H mutation, in CF patients (≥ 6 years of age) who have at least one non-G551D CFTR gating mutation and in children with CF (2 to 5 years old) who have a gating mutation.

Vertex Pharma is also studying Kalydeco in combination with pipeline candidates, VX-809 and VX-661.

With Vertex Pharma working on expanding Kalydeco’s label and strengthening its hepatitis C virus (HCV) portfolio, we expect investor focus to remain on pipeline progress. The successful development of the Kalydeco and VX-809 combination would expand the market for Kalydeco significantly.

Vertex Pharma currently carries a Zacks Rank #3 (Hold). Companies that currently look well-positioned include Alnylam Pharmaceuticals, Inc. (ALNY - Analyst Report), Biogen Idec (BIIB - Analyst Report) and Cytori Therapeutics, Inc. (CYTX - Snapshot Report). All three are Zacks Rank #1 (Strong Buy) stocks.
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%